Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
January 07 2022 - 11:00AM
Edgar (US Regulatory)
UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of January 2022
Commission File Number: 001-40241
LAVA Therapeutics N.V.
(Translation of registrant’s name into English)
Yalelaan 60
3584 CM Utrecht, the Netherlands
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
⌧ Form 20-F ◻ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ◻
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ◻
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LAVA Therapeutics N.V.
|
|
|
|
|
|
|
Date: January 7, 2022
|
|
|
|
By:
|
|
/s/ Edward F. Smith
|
|
|
|
|
|
|
|
Name
|
:
|
Edward F. Smith
|
|
|
|
|
|
|
|
Title:
|
|
Chief Financial Officer
|
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Apr 2023 to Apr 2024
